ivWatch and Aon Join Forces to Transform Patient Safety through ROI Analysis

ivWatch and Aon's Collaborative Approach to Patient Safety

In a groundbreaking initiative, ivWatch, a pioneer in IV safety technology, has partnered with Aon, a prominent global insurance broker, to tackle a significant yet often overlooked issue in healthcare: IV infiltration and extravasation injuries. These adverse events are not only costly but are also underreported, making it essential to quantify their impact on healthcare institutions.

The collaboration focuses on developing a new Return on Investment (ROI) model that illustrates the financial ramifications of severe IV-related injuries. Results from this initiative highlight the potential for early detection technologies to vastly improve patient care while also significantly reducing operational costs for hospitals.

Understanding the Problem

IV infiltration and extravasation injuries occur silently and can lead to severe patient harm. These occurrences often go unnoticed until they escalate into critical complications, resulting in prolonged hospital stays, surgical interventions, and even amputation in extreme cases. Research published in the British Medical Journal noted that existing methods for detecting these injuries are not sufficiently effective, leading to missed diagnoses and ineffective treatment approaches.

ivWatch aims to change this narrative. Through continuous monitoring technology that utilizes near-infrared light and predictive algorithms, ivWatch can alert medical personnel to early signs of infiltration or extravasation. This proactive approach is crucial in a healthcare landscape where approximately 50% of IV insertions result in complications.

Financial Implications of IV Injuries

The newly created ROI model stands as a testament to the cost-saving potential of early intervention. Aon has compiled extensive data, including the largest database of healthcare professional liability claims. This comprehensive analysis provides insights into the long-term financial liabilities that hospitals incur due to complications from IV injuries.

The findings suggest that early detection through ivWatch could translate to annual savings—up to $13.4 million for a typical 150-bed pediatric hospital and between $5.1 million to $7.9 million for other facilities. These figures reflect not only the direct costs related to follow-up care and medical interventions but also the indirect financial burdens like workflow disruptions and negative patient satisfaction ratings.

The Benefits of Early Detection

Comparative studies have shown that implementing continuous monitoring technology can lead to a startling 93% reduction in the severity of IV injuries when contrasted with traditional monitoring methods. By mitigating the risks associated with IV interventions, hospitals can expect a significant decrease in readmission rates, increased patient satisfaction, and enhanced operational efficiency—which in turn can lead to improved revenue.

The study also reveals that hospitals with lower complication rates enjoy higher overall patient satisfaction ratings. For every 10% improvement in these ratings, hospitals can anticipate a 1.5% increase in revenue. This correlation underscores the critical need for hospitals to prioritize safety measures that not only safeguard patients but also fortify their financial health.

Conclusion

Through the collaborative efforts of ivWatch and Aon, the healthcare industry now has access to critical data that sheds light on the financial—and clinical—benefits of integrating continuous IV monitoring technology into hospital protocols. By prioritizing early detection, healthcare institutions are positioned to transform patient safety outcomes while simultaneously protecting their bottom lines.

As ivWatch continues to innovate and Aon refines its analytical capabilities, the partnership promises to redefine how hospitals approach the pressing issues of patient safety and financial sustainability in the healthcare sector. To learn more about this transformative initiative, visit ivWatch.